Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Validation of the Glx Biomarker for Treatment of Moderate Bipolar Depression With NRX-101

NCT03402152 is registered in ClinicalTrials.gov with NeuroRx, Inc. as lead sponsor.

NCT NCT03402152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03402152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Validation of the Glx Biomarker for Treatment of Moderate Bipolar Depression With NRX-101
Lead sponsor
NeuroRx, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
November 1, 2018
Completion date
June 1, 2021
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar depression, suicidal ideation